slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 233,641-233,670
Pages 10,126
Rows per page 30
Component
233,641-233,670 of 303,780
26
The diagram shows a summation of two patient groups (prevalence and incidence-derived relapsed/refractory) to reach a total eligible patient count.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
29
The table compares NXC-201 against Darzalex, CAEL-101, and Birtamimab across various clinical metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
30
Uses a before-and-after framing to illustrate market expansion potential.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
The table highlights low incidence of severe adverse events and management protocols for NXC-201.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
36
The slide highlights safety data (CRS and ICANS) and toxicity management interventions.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
37
NXC-201 is highlighted with an orange border to emphasize its specific regimen.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
The table compares clinical trial inclusion criteria across four different therapies for relapsed/refractory multiple myeloma.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
39
Highlights NXC-201's competitive advantage regarding prior BCMA therapy exclusion.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
The slide uses a numbered process flow layout.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
41
The slide uses cross-trial comparison; disclaimer notes these are not head-to-head results.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes a scientific mechanism of action diagram at the bottom.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
43
The slide uses a segmented horizontal axis to compare two distinct market segments by revenue.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
45
Slide contains three distinct data charts and a summary of clinical trial plans.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
Includes three distinct proof-of-concept data panels (penetration, biodistribution, apoptosis).Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
47
Includes waterfall chart and longitudinal line charts for patient cohorts.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
48
The slide uses a bubble chart to show clinical trial outcomes and a table to detail efficacy/safety metrics across treatment lines.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
49
The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy and safety in heavily pre-treated patients.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
50
Includes survival curves, bioluminescence imaging of mice, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
51
The slide uses a standard biological signaling pathway map to demonstrate the mechanism of action of the drug candidate.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
52
Includes logos for BeiGene and Novartis.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
53
Includes a comparison of iMX-111 size vs IgG antibody, GLUT1 expression across tissues, correlation with cancer stage, and a survival curve.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
The slide uses a combination of mechanism diagrams, clinical trial bar charts, and preclinical mouse model data to validate the therapeutic approach.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
55
The slide uses a bar chart comparison to establish a benchmark for clinical efficacy in the IBD market.Immix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
56
Immix Biopharma | Investor Presentation Deck | 56 slidesImmix Biopharma | Investor Presentation Deck | 56 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
01
Features Kakao Friends characters.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
02
Kakao | Results Presentation Deck | 48 slidesKakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
03
Kakao | Results Presentation Deck | 48 slidesKakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
04
Kakao | Results Presentation Deck | 48 slidesKakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations 1 hit
05
The slide uses a visual metaphor of the Kakao character (Ryan) projecting a cone of light/influence onto the globe.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · ProblemLoop · Logic Chain1 hit
06
The slide uses two distinct horizontal timelines to separate product/service innovation from corporate/structural evolution.Kakao | Results Presentation Deck | 48 slides · Kakao
Conference presentation Investor relations Beat · ProblemLoop · Logic Chain1 hit